- 全部删除
- 您的购物车当前为空
Vobramitamab (AEX-4089)是一种靶向B7-H3抗原(CD276)的人源化单克隆抗体,通过酶切肽链连接子与前驱药物seco-杜卡霉素羟基苯胺氮杂吲哚(seco-DUBA)偶联,形成研究性抗体-药物偶联物MGC018。
为众多的药物研发团队赋能,
让新药发现更简单!
Vobramitamab (AEX-4089)是一种靶向B7-H3抗原(CD276)的人源化单克隆抗体,通过酶切肽链连接子与前驱药物seco-杜卡霉素羟基苯胺氮杂吲哚(seco-DUBA)偶联,形成研究性抗体-药物偶联物MGC018。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 3,290 | In stock | |
5 mg | ¥ 7,260 | In stock | |
10 mg | ¥ 9,790 | In stock | |
25 mg | ¥ 14,500 | In stock | |
50 mg | ¥ 19,600 | In stock |
Vobramitamab 相关产品
产品描述 | Vobramitamab (AEX-4089) is a humanized monoclonal antibody (mAb) targeting the B7-H3 antigen (CD276) which is conjugated to the prodrug seco-duocarmycin hydroxybenzamide azaindole (seco-DUBA) through a enzymatically cleavable peptide-based linker, thereby creating the investigational antibody-drug conjugate (ADC) known as MGC018. |
靶点活性 | NB cell lines:17.8-364 ng/mL (IC50) |
别名 | 沃瑞妥单抗, AEX-4089, AEX4089 |
CAS No. | 2490556-50-6 |
存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容